Skip to Content

Cidofovir Pregnancy and Breastfeeding Warnings

Cidofovir is also known as: Vistide

Cidofovir Pregnancy Warnings

Cidofovir has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of embryotoxicity and fetal harm at doses that are maternally toxic. In addition, animal studies have shown that cidofovir caused reduced testes weight and hypospermia. Such changes may occur in humans and cause infertility. Cidofovir has also been show to be carcinogenic and teratogenic in animal studies. There are no controlled data in human pregnancy. Women of childbearing potential should practice effective contraception during and for one month following discontinuation of treatment with cidofovir. The manufacturer recommends that men use barrier method birth control during and for at least 90 days following discontinuation of cidofovir therapy. Cidofovir should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Cidofovir Breastfeeding Warnings

There are no data on the excretion of cidofovir into human milk. However, the manufacturer considers cidofovir use to be contraindicated during lactation. In addition, HIV-infected mothers should not breast-feed their infants due to the risk of transmission of HIV via breast milk.

See references

References for pregnancy information

  1. "Product Information. Vistide (cidofovir)." Gilead Sciences, Foster City, CA.

References for breastfeeding information

  1. "Product Information. Vistide (cidofovir)." Gilead Sciences, Foster City, CA.
  2. "Infant feeding and transmission of human immunodeficiency virus in the United States." Pediatrics 131 (2013): 391-6
  3. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. National Institute of Health "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL:" ([2011 Sep 14]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.